Pfiz­er is ax­ing its neu­ro­sciences di­vi­sion, lay­ing off 300 and dis­card­ing new drugs

Pfiz­er is start­ing out 2018 by rip­ping up its ear­ly-, mid-stage and pre­clin­i­cal R&D op­er­a­tions fo­cused on neu­ro­sciences and lay­ing off hun­dreds of work­ers en­gaged in the de­vel­op­ment work.

In a state­ment, Pfiz­er $PFE says it is is ax­ing about 300 work­ers in Con­necti­cut and Mass­a­chu­setts — about 100 each in An­dover, Gro­ton and Cam­bridge, where it’s been con­cen­trat­ing its R&D ef­forts — and dis­card­ing a slate of Phase I/II and pre­clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER